Cardiovascular

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...

Challenge An academic group was interested in developing and commercializing an AAV vector-delivered gene therapy for a cardiac indication through the formation of a NewCo. They required assistance...

Challenge: Our client was a US-based venture capital fund, with whom we have a long-standing retainer agreement to provide specialized due diligence support for their fund investment decisions. In...

Challenge A privately-held biotechnology company developing and exploiting a proprietary technology platform for optimizing and controlling gene therapy expression was looking to evolve its business...

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new...